Previous close | 5.0700 |
Open | 5.1100 |
Bid | 4.9100 x 300 |
Ask | 4.9500 x 500 |
Day's range | 4.7950 - 5.1377 |
52-week range | 4.2500 - 22.3000 |
Volume | |
Avg. volume | 914,755 |
Market cap | 245.856M |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.4700 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.92 |
uniQure ( NASDAQ:QURE ) First Quarter 2024 Results Key Financial Results Revenue: US$8.49m (up 59% from 1Q 2023). Net...
~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~ ~ Comprehensive review of operations and options to reduce expenses underway and expected to be completed in mid-2024 ~ LEXINGTON, Mass. and AMSTERDAM, May 07, 20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]